212 related articles for article (PubMed ID: 33396393)
21. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
22. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
23. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
26. Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Wang F; Liu X; Bartholdy BA; Cheng H; Halmos B
Transl Cancer Res; 2019 Oct; 8(6):2425-2438. PubMed ID: 35116995
[TBL] [Abstract][Full Text] [Related]
27. Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring
Chen Y; Hong H; Bao S; Tang H
Front Pharmacol; 2023; 14():1131703. PubMed ID: 38035001
[No Abstract] [Full Text] [Related]
28. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
29. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
30. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
31. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Wang S; Song Y; Liu D
Cancer Lett; 2017 Jan; 385():51-54. PubMed ID: 27840244
[TBL] [Abstract][Full Text] [Related]
32. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.
Jiang T; Zhou C
Transl Lung Cancer Res; 2014 Dec; 3(6):370-2. PubMed ID: 25806323
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.
Ohashi Y; Okamura M; Katayama R; Fang S; Tsutsui S; Akatsuka A; Shan M; Choi HW; Fujita N; Yoshimatsu K; Shiina I; Yamori T; Dan S
Oncotarget; 2018 Jan; 9(2):1641-1655. PubMed ID: 29416720
[TBL] [Abstract][Full Text] [Related]
34. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
[TBL] [Abstract][Full Text] [Related]
35. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
Goldberg ME; Montesion M; Young L; Suh J; Greenbowe J; Kennedy M; Giaccone G; Akerley WL; Dowlati A; Creelan BC; Hicks JK; Hesketh PJ; Kelly KL; Riess JW; Miller VA; Stephens PJ; Frampton GM; Ali S; Gregg JP; Albacker LA
PLoS One; 2018; 13(11):e0208097. PubMed ID: 30481207
[TBL] [Abstract][Full Text] [Related]
36. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
Ménard L; Floc'h N; Martin MJ; Cross DAE
Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
[TBL] [Abstract][Full Text] [Related]
38. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
[TBL] [Abstract][Full Text] [Related]
39. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
[TBL] [Abstract][Full Text] [Related]
40. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Costa DB; Kobayashi SS
Transl Lung Cancer Res; 2015 Dec; 4(6):809-15. PubMed ID: 26798593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
